Sfoglia per Autore
CYR61 DOWN-MODULATION SENSITIZES PROSTATE CANCER CELLS TO ZOLEDRONIC ACID AND DOCETAXEL: A NEW ANTICANCER STRATEGY
2008 Caraglia, ; M, ; Marra, ; M, ; Meo, ; G, ; Zappavigna, S; Vincenzi, ; B, ; Baldi, ; A, ; Rosolowski, ; Loeffler, ; M, ; Tonini, ; G, ; Santini, ; D, ; Budillon, ; A,
CYR61 down-modulation induced by zoledronic acid impairs cell motility and sensitizes prostate cancer cells to docetaxel: A new anti-cancer strategy
2008 Caraglia, ; M, ; Marra, ; M, ; Meo, ; G, ; Addeo, ; Sr, ; Vincenzi, ; B, ; Baldi, ; A, ; Zappavigna, S; Rosolowski, ; M, ; Loeffler, ; B, ; Budillon, ; A, ; Tonini, ; G, ; Santini, ; D,
Bovine serum amine oxidase and spm potentiate docetaxel and interferon-alpha effects in inducing apoptosis on human cancer cells through the generation of oxidative stress.
2008 Marra, M.; Lombardi, A.; Agostinelli, E.; Giuberti, G.; Zappavigna, S.; Tempera, G.; Vitale, G.; Bifulco, M.; ABBRUZZESE SACCARDI, A.; Caraglia, Michele
Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid
2008 Marra, M.; Santini, D.; Tonini, G.; Meo, G.; Zappavigna, S; Abbruzzese, A.; Carteni, G.; Budillon, A.; Caraglia, M.
Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells
2009 Marra, M; Santini, D; Meo, G; Vincenzi, B; Zappavigna, S; Baldi, Alfonso; Rosolowski, M; Tonini, G; Loeffler, M; Lupu, R; Addeo, Sr; Abbruzzese, A; Budillon, A; Caraglia, Michele
Emerging strategies to strengthen the anti-tumour activity of type I IFNs: overcoming survival pathways
2009 Caraglia, Michele; Marra, M.; Lamberts, S. W. J.; Zappavigna, S.; Misso, Gabriella; Cavagnini, F.; Abbruzzese, A.; Hofland, L. J.; Vitale, G.
ZOLEDRONIC ACID INCREASES THE EXPRESSION OF NDRG1 GENE IN HUMAN ANDROGEN-INDEPENDENT PROSTATE CANCER PC3 CELLS
2010 Marra, ; M, ; Ferro, ; M, ; Altieri, ; V, ; Zappavigna, S; Giuberti, ; G, ; Santini, ; D, ; Tonini, ; G, ; Abbruzzese, ; A, ; Caraglia, ; M,
UROTENSIN II RECEPTOR IS INVOLVED IN THE REGULATION OF MOTILITY OF PROSTATE ADENOCARCINOMA CELLS AND PREDICTS THE CLINICAL OUTCOME OF PROSTATE CANCER PATIENTS
2010 Caraglia, Michele; Marra, M; Franco, Renato; Sgambato, A; Zappavigna, S; Striano, S; Marra, L; Gallo, L; Botti, G; Ferro, M; Altieri, V; Novellino, E; Molinari, A; Budillon, A; Grieco, P.
In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: Do nanocarrier properties have a role?
2010 Ostacolo, L; Marra, M; Ungaro, F; Zappavigna, S; Maglio, G; Quaglia, F; Abbruzzese, A; Caraglia, M
Il recettore dell’ urotensina: un nuovo marker per il differenziamento ed il target nel cancro del colon?
2011 Federico, Alessandro; DI DOMENICO, Marina; Romano, Marco; Marra, M.; Zappavigna, S.; Gravina, A. G.; D’Armiento, F. P.; Ippolito, R.; Tuccillo, C.; Greco, P.; Novellino, E.; Loguercio, C.; Abbruzzese, A.; Caraglia, Michele
Espressione del recettore dell’urotensina-II nell’adenocarcinoma del colon umano: studi in vitro ed in vivo.
2011 Federico, Alessandro; DI DOMENICO, Marina; Romano, Marco; Marra, M.; Zappavigna, S.; Gravina, A. G.; D’Armiento, F. P.; Ippolito, R.; Tuccillo, C.; Greco, P.; Novellino, E.; Loguercio, C.; Abbruzzese, A.; Caaraglia, M.
Urotensin-II receptor expression in human colon adenocarcinoma: in vitro and in vivo studies.
2011 Federico, Alessandro; Romano, Marco; Gravina, A. G.; DI DOMENICO, Marina; Marra, M.; Zappavigna, S.; D’Armiento, F. P.; Ippolito, R.; Tuccillo, C.; Grieco, P.; Novellino, E.; Loguercio, C.; Abruzzese, A.; Caraglia, Michele
Valutazione in vitro degli effetti cardiotossici da 5-Fluorouracile per la prevenzione dei danni cardiovascolari negli operatori sanitari professionalmente esposti. [Evaluation in vitro of the cardiotoxic effects of 5-fluorouracil for the prevention of cardiovascular damage in health workers occupationally exposed].
2011 Lamberti, Monica; Caraglia, Michele; Zappavigna, S.; Marra, M.; Ritonnaro, C.; Coppola, M. A.; Naviglio, Silvio; Porto, S.; Marsella, L.; Sannolo, Nicola
Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells.
2011 Grieco, P; Franco, Renato; Bozzuto, G; Toccacieli, L; Sgambato, A; Marra, M; Zappavigna, S; Migaldi, M; Rossi, G; Striano, S; Marra, L; Gallo, L; Cittadini, A; Botti, G; Novellino, E; Molinari, Anna Maria; Budillon, A; Caraglia, Michele
Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes.
2011 Marra, M; Salzano, G; Leonetti, C; Tassone, P; Scarsella, M; Zappavigna, S; Calimeri, T; Franco, Renato; Liguori, G; Cigliana, G; Ascani, R; La Rotonda, Mi; Abbruzzese, A; Tagliaferri, P; Caraglia, Michele; De Rosa, G.
Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
2011 Salzano, G; Marra, M; Porru, M; Zappavigna, S; Abbruzzese, A; La Rotonda, Mi; Leonetti, C; Caraglia, Michele; De Rosa, G.
Nanotechnologies to use zoledronic acid as a potent antitumoral agent
2011 Salzano, G; Marra, M; Leonetti, C; Porru, M; Zappavigna, S; Abbruzzese, A; La Rotonda, Mi; Caraglia, M; De Rosa, G
Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.
2011 Donadelli, M; Dando, I; Zaniboni, T; Costanzo, C; Dalla Pozza, E; Scupoli, Mt; Scarpa, A; Zappavigna, S; Marra, M; Abbruzzese, A; Bifulco, M; Caraglia, Michele; Palmieri, M.
Urotensin-II receptor: a new marker for the differentiation and the target in colon cancer?
2012 Federico, Alessandro; Romano, Marco; Gravina, A. G.; DI DOMENICO, Marina; Marra, M.; Zappavigna, S.; D’Armiento, F. P.; Ippolito, R.; Tuccillo, C.; Grieco, P.; Novellino, E.; Loguercio, Carmelina; Caraglia, Michele
Zoledronic acid encapsulated in self-assembly pegylated nanoparticles as a new delivery system against brain tumors
2012 Zappavigna, S; Luce, A; Panico, A; Porru, M; Salzano, G; Lusa, S; De Rosa, G; Leonetti, C; Caraglia, Michele
Titolo | Data di pubblicazione | Autore(i) | File |
---|---|---|---|
CYR61 DOWN-MODULATION SENSITIZES PROSTATE CANCER CELLS TO ZOLEDRONIC ACID AND DOCETAXEL: A NEW ANTICANCER STRATEGY | 1-gen-2008 | Caraglia, ; M, ; Marra, ; M, ; Meo, ; G, ; Zappavigna, S; Vincenzi, ; B, ; Baldi, ; A, ; Rosolowski, ; Loeffler, ; M, ; Tonini, ; G, ; Santini, ; D, ; Budillon, ; A, | |
CYR61 down-modulation induced by zoledronic acid impairs cell motility and sensitizes prostate cancer cells to docetaxel: A new anti-cancer strategy | 1-gen-2008 | Caraglia, ; M, ; Marra, ; M, ; Meo, ; G, ; Addeo, ; Sr, ; Vincenzi, ; B, ; Baldi, ; A, ; Zappavigna, S; Rosolowski, ; M, ; Loeffler, ; B, ; Budillon, ; A, ; Tonini, ; G, ; Santini, ; D, | |
Bovine serum amine oxidase and spm potentiate docetaxel and interferon-alpha effects in inducing apoptosis on human cancer cells through the generation of oxidative stress. | 1-gen-2008 | Marra, M.; Lombardi, A.; Agostinelli, E.; Giuberti, G.; Zappavigna, S.; Tempera, G.; Vitale, G.; Bifulco, M.; ABBRUZZESE SACCARDI, A.; Caraglia, Michele | |
Molecular and preclinical models enhancing anti-tumour activity of zoledronic acid | 1-gen-2008 | Marra, M.; Santini, D.; Tonini, G.; Meo, G.; Zappavigna, S; Abbruzzese, A.; Carteni, G.; Budillon, A.; Caraglia, M. | |
Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells | 1-gen-2009 | Marra, M; Santini, D; Meo, G; Vincenzi, B; Zappavigna, S; Baldi, Alfonso; Rosolowski, M; Tonini, G; Loeffler, M; Lupu, R; Addeo, Sr; Abbruzzese, A; Budillon, A; Caraglia, Michele | |
Emerging strategies to strengthen the anti-tumour activity of type I IFNs: overcoming survival pathways | 1-gen-2009 | Caraglia, Michele; Marra, M.; Lamberts, S. W. J.; Zappavigna, S.; Misso, Gabriella; Cavagnini, F.; Abbruzzese, A.; Hofland, L. J.; Vitale, G. | |
ZOLEDRONIC ACID INCREASES THE EXPRESSION OF NDRG1 GENE IN HUMAN ANDROGEN-INDEPENDENT PROSTATE CANCER PC3 CELLS | 1-gen-2010 | Marra, ; M, ; Ferro, ; M, ; Altieri, ; V, ; Zappavigna, S; Giuberti, ; G, ; Santini, ; D, ; Tonini, ; G, ; Abbruzzese, ; A, ; Caraglia, ; M, | |
UROTENSIN II RECEPTOR IS INVOLVED IN THE REGULATION OF MOTILITY OF PROSTATE ADENOCARCINOMA CELLS AND PREDICTS THE CLINICAL OUTCOME OF PROSTATE CANCER PATIENTS | 1-gen-2010 | Caraglia, Michele; Marra, M; Franco, Renato; Sgambato, A; Zappavigna, S; Striano, S; Marra, L; Gallo, L; Botti, G; Ferro, M; Altieri, V; Novellino, E; Molinari, A; Budillon, A; Grieco, P. | |
In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: Do nanocarrier properties have a role? | 1-gen-2010 | Ostacolo, L; Marra, M; Ungaro, F; Zappavigna, S; Maglio, G; Quaglia, F; Abbruzzese, A; Caraglia, M | |
Il recettore dell’ urotensina: un nuovo marker per il differenziamento ed il target nel cancro del colon? | 1-gen-2011 | Federico, Alessandro; DI DOMENICO, Marina; Romano, Marco; Marra, M.; Zappavigna, S.; Gravina, A. G.; D’Armiento, F. P.; Ippolito, R.; Tuccillo, C.; Greco, P.; Novellino, E.; Loguercio, C.; Abbruzzese, A.; Caraglia, Michele | |
Espressione del recettore dell’urotensina-II nell’adenocarcinoma del colon umano: studi in vitro ed in vivo. | 1-gen-2011 | Federico, Alessandro; DI DOMENICO, Marina; Romano, Marco; Marra, M.; Zappavigna, S.; Gravina, A. G.; D’Armiento, F. P.; Ippolito, R.; Tuccillo, C.; Greco, P.; Novellino, E.; Loguercio, C.; Abbruzzese, A.; Caaraglia, M. | |
Urotensin-II receptor expression in human colon adenocarcinoma: in vitro and in vivo studies. | 1-gen-2011 | Federico, Alessandro; Romano, Marco; Gravina, A. G.; DI DOMENICO, Marina; Marra, M.; Zappavigna, S.; D’Armiento, F. P.; Ippolito, R.; Tuccillo, C.; Grieco, P.; Novellino, E.; Loguercio, C.; Abruzzese, A.; Caraglia, Michele | |
Valutazione in vitro degli effetti cardiotossici da 5-Fluorouracile per la prevenzione dei danni cardiovascolari negli operatori sanitari professionalmente esposti. [Evaluation in vitro of the cardiotoxic effects of 5-fluorouracil for the prevention of cardiovascular damage in health workers occupationally exposed]. | 1-gen-2011 | Lamberti, Monica; Caraglia, Michele; Zappavigna, S.; Marra, M.; Ritonnaro, C.; Coppola, M. A.; Naviglio, Silvio; Porto, S.; Marsella, L.; Sannolo, Nicola | |
Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells. | 1-gen-2011 | Grieco, P; Franco, Renato; Bozzuto, G; Toccacieli, L; Sgambato, A; Marra, M; Zappavigna, S; Migaldi, M; Rossi, G; Striano, S; Marra, L; Gallo, L; Cittadini, A; Botti, G; Novellino, E; Molinari, Anna Maria; Budillon, A; Caraglia, Michele | |
Nanotechnologies to use bisphosphonates as potent anticancer agents: the effects of zoledronic acid encapsulated into liposomes. | 1-gen-2011 | Marra, M; Salzano, G; Leonetti, C; Tassone, P; Scarsella, M; Zappavigna, S; Calimeri, T; Franco, Renato; Liguori, G; Cigliana, G; Ascani, R; La Rotonda, Mi; Abbruzzese, A; Tagliaferri, P; Caraglia, Michele; De Rosa, G. | |
Self-assembly nanoparticles for the delivery of bisphosphonates into tumors. | 1-gen-2011 | Salzano, G; Marra, M; Porru, M; Zappavigna, S; Abbruzzese, A; La Rotonda, Mi; Leonetti, C; Caraglia, Michele; De Rosa, G. | |
Nanotechnologies to use zoledronic acid as a potent antitumoral agent | 1-gen-2011 | Salzano, G; Marra, M; Leonetti, C; Porru, M; Zappavigna, S; Abbruzzese, A; La Rotonda, Mi; Caraglia, M; De Rosa, G | |
Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. | 1-gen-2011 | Donadelli, M; Dando, I; Zaniboni, T; Costanzo, C; Dalla Pozza, E; Scupoli, Mt; Scarpa, A; Zappavigna, S; Marra, M; Abbruzzese, A; Bifulco, M; Caraglia, Michele; Palmieri, M. | |
Urotensin-II receptor: a new marker for the differentiation and the target in colon cancer? | 1-gen-2012 | Federico, Alessandro; Romano, Marco; Gravina, A. G.; DI DOMENICO, Marina; Marra, M.; Zappavigna, S.; D’Armiento, F. P.; Ippolito, R.; Tuccillo, C.; Grieco, P.; Novellino, E.; Loguercio, Carmelina; Caraglia, Michele | |
Zoledronic acid encapsulated in self-assembly pegylated nanoparticles as a new delivery system against brain tumors | 1-gen-2012 | Zappavigna, S; Luce, A; Panico, A; Porru, M; Salzano, G; Lusa, S; De Rosa, G; Leonetti, C; Caraglia, Michele |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile